Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
Discovery Biology Management, Novo Nordisk, DK-2760 Maaloev, Denmark. lbkn@novonordisk.com
Lotte Bjerre
LB
Knudsen
D000595:Amino Acid Sequence; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005934:Glucagon / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D011498:Protein Precursors / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon